Dynamics of Chronic Myeloid Leukemia Under Imatinib Treatment: A Study of Resistance Development

被引:0
作者
Badralexi, Irina [1 ]
Bordei, Ana-Maria [2 ]
Halanay, Andrei [3 ]
Radulescu, Ileana Rodica [1 ]
机构
[1] Natl Univ Sci & Technol, Politehn Bucharest, Dept Math Methods & Models, Bucharest 060042, Romania
[2] Natl Inst Aerosp Res Elie Carafoli INCAS Bucharest, Bucharest 061126, Romania
[3] Natl Univ Sci & Technol, Politehn Bucharest, Dept Math & Informat, Bucharest 060042, Romania
关键词
chronic myeloid leukemia; asymmetric division; immune system; imatinib; delay differential equations; MATHEMATICAL-MODEL; DELAY SYSTEMS; STABILITY; HEMATOPOIESIS; BIOLOGY; CELLS;
D O I
10.3390/math12243937
中图分类号
O1 [数学];
学科分类号
0701 ; 070101 ;
摘要
Chronic myeloid leukemia (CML) is a hematological disorder characterized by the abnormal proliferation of leukemic cells. This study aims to model the dynamics of leukemic and healthy cell populations in CML, considering the role of the immune system and the effects of treatment with Imatinib. The model also addresses the development of treatment resistance in cells, following the Goldie-Coldman hypothesis. We employ a system of delay differential equations to simulate the interactions between leukemic cells, healthy cells, and the immune system under treatment. The results provide insights into the dynamic balance between leukemic cells, healthy cells, and immune responses, and the impact of developing resistance on treatment outcomes.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib
    Robert C. Jackson
    Tomas Radivoyevitch
    The AAPS Journal, 2016, 18 : 914 - 922
  • [42] Alterations in Sialylation Patterns are Significantly Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia
    Patel, Kinjal D.
    De, Maitri
    Jethva, Disha D.
    Rathod, Bharati S.
    Patel, Prabhudas S.
    ARCHIVES OF MEDICAL RESEARCH, 2022, 53 (01) : 51 - 58
  • [43] Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - Evaluation of response and resistance
    Paschka, P
    Merx, K
    Hochhaus, A
    ACTA HAEMATOLOGICA, 2004, 112 (1-2) : 85 - 92
  • [44] t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia
    Dencic-Fekete, Marija
    Dordevic, Vesna
    Storlazzi, Clelia Tiziana
    Jankovic, Gradimir
    Bogdanovic, Andrija
    Jovanovic, Jelica
    Rocchi, Mariano
    Todoric-Zivanovic, Biljana
    Strnad, Milica
    Gotic, Mirjana
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (04) : 508 - 512
  • [45] Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells
    Baran, Yusuf
    Ural, Ali Ugur
    Gunduz, Ufuk
    HEMATOLOGY, 2007, 12 (06) : 497 - 503
  • [46] Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity
    Lars Harbaum
    Andreas Marx
    Eray Goekkurt
    Philippe Schafhausen
    Djordje Atanackovic
    International Journal of Hematology, 2014, 99 : 91 - 94
  • [47] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Guoqing Wei
    Shamudheen Rafiyath
    Delong Liu
    Journal of Hematology & Oncology, 3
  • [48] Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
    D Bixby
    M Talpaz
    Leukemia, 2011, 25 : 7 - 22
  • [49] Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
    Bixby, D.
    Talpaz, M.
    LEUKEMIA, 2011, 25 (01) : 7 - 22
  • [50] Ex vivo platelet morphology assessment of chronic myeloid leukemia patients before and after Imatinib treatment
    Repsold, Lisa
    Pool, Roger
    Karodia, Mohammed
    Tintinger, Gregory
    Joubert, Anna Margaretha
    MICROSCOPY RESEARCH AND TECHNIQUE, 2022, 85 (06) : 2222 - 2233